




FIG. 1

NEST-ID (Sex)	Stage Pre-treatment (clinical)		Stage Post-treatment (pathologic)		Path Response	Adverse events
9*(M)	IIIC	T3dN2b	→	- T0N0	100%	No
7*(M)	I	T2N0	→	- T0NX	100%	G1
11(M)	IIIB	T3N1a	→	- T0N0	100%	G3
6(F)	IIIB	T3N2a	→	I T2N0	98%	G1
8(F)	IIIC	T3bN2b	→	IIA T3N0	50%	G1/G3
5(M)	IIIC	T3N2b	→	- T0N0	100%	No
1(M)	IIIA	T2N1a	→	I T1N0	90%	No
3*(F)	IIIB	T3aN1b	→	IIIC T4aN2b	10%	G1
10(F)	IIIC	T3dN2b	→	IIA T3N0	50%	No
2*(F)	IIIB	T3bN2a	→	I T1N0	85%	G1/G2
12(F)		TXN0	→	IIIA T2N1a	0%	No
4(M)	IIIB	T3N2a	→	IIIB T3N1b	25%	No

FIG. 2A




FIG. 2B




FIG. 3B

FIG. 3A




FIG. 4




FIG. 5C




FIG. 5E

FIG. 5D




FIG. 6





FIG. 7

9/17


$$\frac{\infty}{E}G$$

10/17




FIG. 9A




FIG. 9B

12/17




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C

Biopsy Resection: Tumor area 1 Resection: Tumor area 2




FIG. 10D